<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635594</url>
  </required_header>
  <id_info>
    <org_study_id>BTS884/15</org_study_id>
    <nct_id>NCT02635594</nct_id>
  </id_info>
  <brief_title>Effects of Carnipure® Tartrate on Postprandial Endothelial Function and Recovery</brief_title>
  <official_title>Effects of Carnipure® Tartrate on Postprandial Endothelial Function and Recovery From Physical Exertion in Healthy People - a Randomized, Double-blind, Placebo-controlled, Two-way Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lonza Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lonza Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of 4 weeks supplementation with Carnipure® tartrate on endothelial function and
      parameters of recovery after physical exertion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial endothelial function</measure>
    <time_frame>after 4 weeks supplementation</time_frame>
    <description>postprandial endothelial function assessed after 4 weeks supplementation with verum in comparison to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal strength (Nm) before and after exhaustive exercise</measure>
    <time_frame>immediately before, 0h, 2h, 24h, 48h,</time_frame>
    <description>Maxiaml strength assessed after 4 weeks supplementation with verum in comparison to placebo at different time points, each (pre exhaustive exercise, immediately after, 2h, 24h and 48h after)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain before and after exhaustive exercise (VAS)</measure>
    <time_frame>immediately before, 0h, 2h, 24h, 48h,</time_frame>
    <description>Pain assessed after 4 weeks supplementation with verum in comparison to placebo at different time points, each (pre exhaustive exercise, immediately after, 2h, 24h and 48h after)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatin Kinase (CK) before and after exhaustive exercise</measure>
    <time_frame>immediately before, 0h, 2h, 24h, 48h,</time_frame>
    <description>Assessement of CK after 4 weeks supplementation with verum in comparison to placebo at different time points, each (pre exhaustive exercise, immediately after, 2h, 24h and 48h after)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myoglobine (Mb) before and after exhaustive exercise</measure>
    <time_frame>immediately before, 0h, 2h, 24h, 48h,</time_frame>
    <description>Assessement of Mb after 4 weeks supplementation with verum in comparison to placebo at different time points, each (pre exhaustive exercise, immediately after, 2h, 24h and 48h after)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker for vascular health</measure>
    <time_frame>after 4 weeks supplementation</time_frame>
    <description>Biomarker for vascular health assessed after 4 weeks supplementation with verum in comparison to placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>after 4 weeks supplementation</time_frame>
    <description>Adverse events assessed after 4 weeks supplementation with verum and placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood routine parameters</measure>
    <time_frame>at screening and after 4 weeks supplementation</time_frame>
    <description>Blood routine parameters (differentiated haemogram; blood lipids; glucose; kreatinin) as safety parameters assessed at screening and after 4 weeks supplementation with verum and placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Tolerability (questionnaire)</measure>
    <time_frame>after 4 weeks supplementation</time_frame>
    <description>Tolerability assessed after 4 weeks supplementation with verum in comparison to placebo</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Recovery</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Carnipure® tartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1000mg cellulose + 475mg L-tartaric acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Carnitine</intervention_name>
    <description>1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate</description>
    <arm_group_label>Carnipure® tartrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1000mg cellulose + 475mg L-tartaric acid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women between 25 and 45 years

          -  Body mass index (BMI) between 20 and 30 kg/m²

          -  Non-smoker

          -  Physically active 1-2 times per week

        Exclusion Criteria:

          1. Competitive athlete or performance of high intensity training

          2. Vegan

          3. Nutrition with high portion of meat (&gt; 3 times meat per week).

          4. Injury at the finger

          5. History or presence of significant cardiovascular disease or co-morbidities (i.e.,
             diabetes, etc.)

          6. Known allergy to ingredients of study preparation

          7. Disturbed absorption due to changes in the gastrointestinal tract (e.g., resections,
             diverticula, blind-loop syndrome)

          8. Hypo/ hypertension or taking anti hypo/ hypertension medication

          9. Untreated thyroid dysfunction

         10. Atherosclerosis or other relevant musculoskeletal diseases/ injuries

         11. Anemia (women: Hb &lt;11 g/ dl; men: 12.5 g/ dl)

         12. Eating disorder

         13. Present or recent use of drugs and dietary supplements that affect the endothelial
             function, re-covery or lipid status 2 months before or during the study (e.g.
             L-Carnitine, Arginine, omega3 FA, polyphenol rich supplements (e.g. OPC, cacao, etc)
             antihypertensive drugs, anti hyperlipidemic drugs, regular intake of protein-shakes
             etc.)

         14. Subjects not willing to abstain from intake of analgesic medication 24 hours prior to
             and during visit 1b and 3b.

         15. Female patients that are pregnant or nursing

         16. Night shift worker

         17. Donation of blood or similar blood loss within the previous 30 days before screening;

         18. Participation in a clinical trial with an investigational product within 30 days
             before screening

         19. Known alcohol abuse or drug abuse

         20. Known infection of human immunodeficiency virus (HIV) or hepatitis B or C

         21. Known lactose intolerance, dairy protein allergy or allergy to nuts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Menzel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioTeSys GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioTeSys GmbH</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Württemberg</state>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

